Business Context and Reporting Period
This Form 6-K filing by GSK plc reports the results of the 25th Annual General Meeting (AGM) held on May 7, 2025. The meeting was conducted as a hybrid event at The Landmark London, allowing for both in-person and virtual participation. The filing details the voting outcomes for 25 resolutions, including the adoption of the 2024 Annual Report, director elections, and auditor appointments.
Key Financial Metrics
The filing text does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting statistics.
Material Changes Versus Prior Period
Comparative data regarding shareholder participation and capital structure between the 2025 and 2024 AGMs includes:
- Issued Share Capital: Decreased from 4,314,108,510 shares in 2024 to 4,109,037,095 shares in 2025 (excluding Treasury Shares).
- Shareholder Participation: The percentage of issued share capital represented by votes cast and withheld increased from 73.11% in 2024 to 74.21% in 2025.
- Shareholder Population: The total number of shareholders grew significantly from 60,448 in 2024 to 86,241 in 2025.
- Proxy Lodgement: The percentage of shareholders lodging proxies decreased slightly from 4.77% in 2024 to 4.34% in 2025.
Guidance, Outlook, and Voting Results
All 25 resolutions presented at the AGM were passed. Key voting outcomes include:
- Annual Report Adoption: Resolution 1 to receive and adopt the 2024 Annual Report passed with 99.82% of votes cast in favor.
- Remuneration: The Annual report on remuneration (Resolution 2) passed with 92.46% support, while the Remuneration policy (Resolution 3) passed with 93.10% support.
- Director Elections: All director elections (Resolutions 4-15) were approved with support ranging from 96.36% to 99.89%. Notably, the re-election of Wendy Becker received the lowest support at 96.36%.
- Shareholder Authority: Special resolutions regarding the disapplication of pre-emption rights and authority to purchase own shares were approved with majorities exceeding 95%.
The filing contains no management commentary on future financial guidance, risks, or contingencies beyond the standard disclosure of voting results.
Important Facts for Investor Verification
- Verify the full text of the 2024 Annual Report and Remuneration Report referenced in the voting results.
- Confirm the reduction in issued share capital from 2024 to 2025 to understand the impact of share buybacks or treasury share movements.
- Review the specific details of the "GSK Share Value Plan" approved under Resolution 25.
- Check the company website for the full text of resolutions and the detailed breakdown of votes withheld.